PROCEPT BioRobotics (PRCT)
(Real Time Quote from BATS)
$49.74 USD
-1.34 (-2.62%)
Updated Apr 19, 2024 01:04 PM ET
3-Hold of 5 3
D Value D Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for PROCEPT BioRobotics Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 257 | 223 | 304 | 100 | -99,999 |
Receivables | 48 | 15 | 4 | 2 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 40 | 29 | 13 | 7 | NA |
Other Current Assets | 5 | 6 | 4 | 2 | NA |
Total Current Assets | 351 | 273 | 326 | 110 | NA |
Net Property & Equipment | 29 | 9 | 5 | 8 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 1 | 1 | 2 | 2 | NA |
Deposits & Other Assets | 4 | 3 | 1 | 1 | NA |
Total Assets | 405 | 309 | 337 | 126 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 5 | NA |
Accounts Payable | 14 | 9 | 2 | 1 | NA |
Current Portion Long-Term Debt | 2 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 17 | 13 | 6 | 5 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 12 | 10 | 6 | 2 | NA |
Total Current Liabilities | 46 | 35 | 16 | 15 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 51 | 53 | 52 | 46 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 1 | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 124 | 112 | 70 | 65 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 244 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 735 | 546 | 529 | 19 | NA |
Retained Earnings | -455 | -349 | -262 | -202 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 281 | 197 | 267 | 61 | NA |
Total Liabilities & Shareholder's Equity | 405 | 309 | 337 | 126 | NA |
Total Common Equity | 281 | 197 | 267 | -183 | 0 |
Shares Outstanding | 50.50 | 44.70 | 43.50 | NA | NA |
Book Value Per Share | 5.56 | 4.41 | 6.14 | 0.00 | 0.00 |
Fiscal Year End for PROCEPT BioRobotics Corporation falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 257 | 288 | 150 | 182 |
Receivables | NA | 48 | 35 | 33 | 21 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 40 | 42 | 43 | 39 |
Other Current Assets | NA | 5 | 4 | 4 | 4 |
Total Current Assets | NA | 351 | 369 | 230 | 246 |
Net Property & Equipment | NA | 29 | 27 | 16 | 12 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 1 | 1 | 1 | 1 |
Deposits & Other Assets | NA | 4 | 3 | 3 | 3 |
Total Assets | NA | 405 | 421 | 272 | 284 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 14 | 14 | 10 | 10 |
Current Portion Long-Term Debt | NA | 2 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 17 | 13 | 10 | 7 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 12 | 13 | 14 | 12 |
Total Current Liabilities | NA | 46 | 41 | 36 | 33 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 1 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 51 | 53 | 53 | 53 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 124 | 122 | 117 | 111 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 735 | 726 | 558 | 550 |
Retained Earnings | NA | -455 | -427 | -402 | -377 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 281 | 299 | 156 | 173 |
Total Liabilities & Shareholder's Equity | NA | 405 | 421 | 272 | 284 |
Total Common Equity | 0 | 281 | 299 | 156 | 173 |
Shares Outstanding | 50.90 | 50.50 | 50.50 | 45.20 | 45.00 |
Book Value Per Share | 0.00 | 5.56 | 5.93 | 3.45 | 3.85 |